The phase III CheckMate -9ER trial, in which Opdivo (nivolumab)in combination with Cabometyx (cabozantinib) demonstrated significant improvements across all efficacy endpoints, including overall survival, in previously untreated advanced renal cell carcinoma.
Results from the phase III CheckMate -577 trial demonstrated that adjuvant treatment with Opdivo (nivolumab) showed a statistically significant and clinically meaningful improvement in disease-free survival, the trial's primary endpoint, compared to placebo in patients with esophageal or gastroesophageal junction cancer following neoadjuvant chemoradiation therapy and tumor resection.
The phase III CheckMate -649 demonstrated that first-line treatment with Opdivo (nivolumab) plus chemotherapy showed a statistically significant and clinically meaningful improvement in the overall survival and progression-free survival of patients with unresectable advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma compared to treatment with chemotherapy alone.
The phase III SOLO-1 trial demonstrated a long-term progression-free survival benefit of Lynparza versus placebo as a first-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated ovarian cancer who were in complete or partial response to platinum-based chemotherapy.
Verzenio significantly reduces risk of cancer recurrence in HR+, HER2- high risk early breast cancer
Verzenio (abemaciclib) in combination with standard adjuvant endocrine therapy significantly decreased the risk of breast cancer recurrence by 25% compared to standard adjuvant ET alone for people with hormone receptor-positive, human epidermal growth factor receptor 2-negative high risk early breast cancer (HR: 0.747; 95% CI: 0.598, 0.932; p = 0.0096).
The phase III trial of Padcev (enfortumab vedotin-ejfv) met its primary endpoint of overall survival compared to chemotherapy.
The combined use of aspirin, statins, and metformin is associated with decreased lung cancer incidence and mortality, according to a study published in the Journal of Thoracic Oncology, the journal of the International Association for the Study of Lung Cancer.
Patients treated for bladder cancer with a surgery known as radical cystectomy have worse outcomes if they are smokers, according to a systematic review and meta-analysis by Keck Medicine of USC. The study appeared in the Journal of Urology.
The EA61411 study conducted by ECOG-ACRIN Cancer Research Group has begun its phase III portion.
Despite progress, adolescents and young adults face substantial cancer disparities by race/ethnicity
A new report examining cancer in adolescents and young adults defined as diagnoses occurring during ages 15 to 39, provides updated estimates of the contemporary cancer burden in this age group, predicting that 89,500 cases and 9,270 deaths will occur in 2020 in the United States. The report appears in CA: A Cancer Journal for Clinicians.
